Clinical trials: Overweight and/or Obesity
Obesity
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week.
- Trial name
- NCT06326060
- Testing
- NNC0519-0130, Tirzepatide
- Where
- 70 sites in United States, Australia and 1 more
- Volunteers
- 354 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
This study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in human body, and what human body does to the study medicine.
- Trial name
- NCT06719011
- Testing
- NNC0174-1213 A, Cagrilintide B
- Where
- 2 sites in United States
- Volunteers
- 178 people
- Sponsor
- Novo Nordisk A/S
Obesity
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with…
- Trial name
- GZBF (NCT07467447)
- Testing
- Retatrutide (LY3437943), Standardized diet and physical activity counseling throughout the study.
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Hudson Biotech
Depression
A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of major depression in overweight or obese subjects.
- Trial name
- NCT00624858
- Testing
- naltrexone SR 32 mg/ bupropion SR 360 mg daily
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity
Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMF-650 in Otherwise Healthy Overweight or Obese…
- Trial name
- NCT07223216
- Testing
- BMF-650
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Biomea Fusion Inc.
Hypercholesterolemia, Dyslipidaemias
An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation
The investigational drugs administered in this study activate proteins called PPARs. Data in the scientific literature on PPARs, as well as animal data and early clinical data generated by GSK with these drugs, suggest that…
- Conditions
- Hypercholesterolemia, Dyslipidaemias, Obesity
- Trial name
- NCT00388180
- Testing
- GW501516, GW590735
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway…
- Trial name
- MARITIME-OSA-1 (NCT07225686)
- Testing
- Maridebart cafraglutide
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Obesity
Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans
The purpose of this study is to retrospectively and systematically review records of overweight and obese Medifast Weight Control Center (MWCC) members who have been assigned to the 5 \& 2 \& 2 Plan or the 4 \& 2 \& 1 Plan for…
- Trial name
- NCT02150837
- Testing
- 5 & 2 & 2 Plan, 4 & 2 & 1 Plan
- Where
- United States
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Medifast, Inc.
Obesity
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06568731
- Testing
- Danuglipron
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234.
- Trial name
- NCT07220954
- Testing
- AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2 (high concentration)
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
End Stage Renal Disease, Renal Impairment
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection…
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Trial name
- NCT07793929
- Testing
- Ribupatide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kailera
Overweight or Obesity
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.
- Trial name
- NCT06396429
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 567 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Obesity
Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients
The purpose of this study is to assess the safety and weight loss effect of lorcaserin at the end of the first year of treatment (Week 48) in overweight and Chinese adult obese patients compared to placebo.
- Trial name
- NCT03720574
- Testing
- Lorcaserin 10 mg BID
- Where
- 9 sites in China
- Volunteers
- 100 people
- Sponsor
- Kanion & Huawe Medicine Co.,Ltd
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Hypertension
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of…
- Trial name
- NCT06948422
- Testing
- Orforglipron
- Where
- 100 sites in United States, Argentina and 9 more
- Volunteers
- 974 people
- Sponsor
- Eli Lilly and Company
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Obesity, Overweight
A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to assess how well LY4329090 is tolerated and what side effects may occur in healthy participants with obesity or overweight.
- Trial name
- NCT07808073
- Testing
- LY4329090
- Where
- 3 sites in United States, Singapore
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Metabolism and Nutrition Disorder, Obesity
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for…
- Trial name
- NCT02870231
- Testing
- NNC9204-0530, liraglutide
- Where
- 2 sites in United States
- Volunteers
- 187 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study of LY3457263 in Obese Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants.
- Trial name
- NCT05582096
- Testing
- LY3457263, Tirzepatide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company